VEGF/Ang-2 inhibitor ‘potentially exciting development’ in diabetic macular edema

Sunir J. Garg, MD, FACS, FASRS, discussed findings from a proof-of-concept clinical trial comparing OLN324, a bispecific antibody targeting VEGF and Ang-2, with faricimab in patients with diabetic macular edema in this video with Healio.The results were presented at the American Society of Retina Specialists annual meeting.